BioCryst Pharma (BCRX) Misses Q4 EPS by 5c, Miss on Revenues; Offers FY18 Financial Guidance & Clinical Outlook
Go back to BioCryst Pharma (BCRX) Misses Q4 EPS by 5c, Miss on Revenues; Offers FY18 Financial Guidance & Clinical Outlook| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 8.68 -0.02 (0.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.70 | 52 Week High | $10.98 | |||
| Open | $8.60 | 52 Week Low | $1.63 | |||
| Day High | $8.84 | P/E | N/A | |||
| Day Low | $8.54 | EPS | $-0.68 | |||
| Volume | 1,257,593 | |||||
